Ropanicant safety and efficacy study for major depression
About this title
Read the official source — NCT06126497Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.
Understand this study
What did researchers investigate?
Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Bellflower and 9 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
- Recruitment status
- Completed
- Enrollment listed in the registry
- 41
- Sponsor
- Suven Life Sciences Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06126497
- Official title
Show the full official title
An Open-Label Study Evaluating the Safety and Efficacy of Ropanicant in Participants With Moderate to Severe Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
Bellflower · Orange · Torrance
7 more locations
- Miami Lakes
- Decatur
- Savannah
- Flowood
- North Canton
- Murray
- Everett
Interested in joining this study?
Questions about this study
What did researchers investigate?
Researchers studied Ropanicant, tracking side effects to assess safety in people with depression.
Who is behind this study?
The study sponsor is Suven Life Sciences Limited.
Did this study involve medication?
Yes. The study involved medication, including Ropanicant.
Who was this study for?
This study was for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
